Diabetes Metab J.  2023 Nov;47(6):769-770. 10.4093/dmj.2023.0351.

Navigating the Future of Diabetes Treatment with New Drugs: Focusing on the Possibilities and Prospects of Enavogliflozin

• Rhee SY

• KMID: 2548153
• DOI: http://doi.org/10.4093/dmj.2023.0351

Reference

1. Kim SH, Lee SH, Yim HJ. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry. Arch Pharm Res. 2013; 36:1185–8.

2. McCormack PL. Evogliptin: first global approval. Drugs. 2015; 75:2045–9.

3. Han KA, Kim YH, Kim DM, Lee BW, Chon S, Sohn TS, et al. Efficacy and safety of enavogliflozin versus dapagliflozin as add-on to metformin in patients with type 2 diabetes mellitus: a 24-week, double-blind, randomized trial. Diabetes Metab J. 2023; 47:796–807.

4. Kim HJ, Park SO, Ko SH, Rhee SY, Hur KY, Kim NH, et al. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus: a position statement of the Korean Diabetes Association. Diabetes Metab J. 2017; 41:423–9.

5. Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021; 385:896–907.